|
1.
|
Maheswaran S and Haber DA: Circulating
tumor cells: a window into cancer biology and metastasis. Curr Opin
Genet Dev. 20:96–99. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Pantel K, Alix-Panabieres C and Riethdorf
S: Cancer micro-metastases. Nat Rev Clin Oncol. 6:339–351. 2009.
View Article : Google Scholar
|
|
3.
|
Pantel K, Brakenhoff RH and Brandt B:
Detection, clinical relevance and specific biological properties of
disseminating tumour cells. Nat Rev Cancer. 8:329–340. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Ashworth A: A case of cancer in which
cells similar to those in the tumours were seen in the blood after
death. Aust Med J. 14:146–149. 1869.
|
|
5.
|
Mocellin S, Keilholz U, Rossi CR and Nitti
D: Circulating tumor cells: the 'leukemic phase' of solid cancers.
Trends Mol Med. 12:130–139. 2006.
|
|
6.
|
Peach G, Kim C, Zacharakis E, Purkayastha
S and Ziprin P: Prognostic significance of circulating tumour cells
following surgical resection of colorectal cancers: a systematic
review. Br J Cancer. 102:1327–1334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Alunni-Fabbroni M and Sandri MT:
Circulating tumour cells in clinical practice: methods of detection
and possible characterization. Methods. 50:289–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Allan AL and Keeney M: Circulating tumor
cell analysis: technical and statistical considerations for
application to the clinic. J Oncol. 2010:4262182010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Panteleakou Z, Lembessis P, Sourla A, et
al: Detection of circulating tumor cells in prostate cancer
patients: methodological pitfalls and clinical relevance. Mol Med.
15:101–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Dotan E, Cohen SJ, Alpaugh KR and Meropol
NJ: Circulating tumor cells: evolving evidence and future
challenges. Oncologist. 14:1070–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ring A, Smith IE and Dowsett M:
Circulating tumour cells in breast cancer. Lancet Oncol. 5:79–88.
2004. View Article : Google Scholar
|
|
12.
|
Nagrath S, Sequist LV, Maheswaran S, et
al: Isolation of rare circulating tumour cells in cancer patients
by microchip technology. Nature. 450:1235–1239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sequist LV, Nagrath S, Toner M, Haber DA
and Lynch TJ: The CTC-chip: an exciting new tool to detect
circulating tumor cells in lung cancer patients. J Thorac Oncol.
4:281–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Cristofanilli M: The biological
information obtainable from circulating tumor cells. Breast.
18(Suppl 3): 38–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Botteri E, Sandri MT, Bagnardi V, et al:
Modeling the relationship between circulating tumour cells number
and prognosis of metastatic breast cancer. Breast Cancer Res Treat.
122:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Nole F, Munzone E, Zorzino L, et al:
Variation of circulating tumor cell levels during treatment of
metastatic breast cancer: prognostic and therapeutic implications.
Ann Oncol. 19:891–897. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Apostolaki S, Perraki M, Pallis A, et al:
Circulating HER2 mRNA-positive cells in the peripheral blood of
patients with stage I and II breast cancer after the administration
of adjuvant chemotherapy: evaluation of their clinical relevance.
Ann Oncol. 18:851–858. 2007. View Article : Google Scholar
|
|
18.
|
Cristofanilli M, Hayes DF, Budd GT, et al:
Circulating tumor cells: a novel prognostic factor for newly
diagnosed metastatic breast cancer. J Clin Oncol. 23:1420–1430.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Cristofanilli M, Budd GT, Ellis MJ, et al:
Circulating tumor cells, disease progression, and survival in
metastatic breast cancer. N Engl J Med. 351:781–791. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Takeuchi H and Kitagawa Y: Circulating
tumor cells in gastrointestinal cancer. J Hepatobiliary Pancreat
Surg. 17:577–582. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Xenidis N, Ignatiadis M, Apostolaki S, et
al: Cytokeratin-19 mRNA-positive circulating tumor cells after
adjuvant chemotherapy in patients with early breast cancer. J Clin
Oncol. 27:2177–2184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wu C, Hao H, Li L, et al: Preliminary
investigation of the clinical significance of detecting circulating
tumor cells enriched from lung cancer patients. J Thorac Oncol.
4:30–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Wong SC, Chan CM, Ma BB, et al: Clinical
significance of cytokeratin 20-positive circulating tumor cells
detected by a refined immunomagnetic enrichment assay in colorectal
cancer patients. Clin Cancer Res. 15:1005–1012. 2009. View Article : Google Scholar
|
|
24.
|
Scher HI, Jia X, de Bono JS, et al:
Circulating tumour cells as prognostic markers in progressive,
castration-resistant prostate cancer: a reanalysis of IMMC38 trial
data. Lancet Oncol. 10:233–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Stakenborg T, Liu C, Henry O, et al:
Automated genotyping of circulating tumor cells. Expert Rev Mol
Diagn. 10:723–729. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Luzzi KJ, MacDonald IC, Schmidt EE, et al:
Multistep nature of metastatic inefficiency: dormancy of solitary
cells after successful extravasation and limited survival of early
micrometastases. Am J Pathol. 153:865–873. 1998. View Article : Google Scholar
|
|
27.
|
Chang YS, di Tomaso E, McDonald DM, Jones
R, Jain RK and Munn LL: Mosaic blood vessels in tumors: frequency
of cancer cells in contact with flowing blood. Proc Natl Acad Sci
USA. 97:14608–14613. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Shaffer DR, Leversha MA, Danila DC, et al:
Circulating tumor cell analysis in patients with progressive
castration-resistant prostate cancer. Clin Cancer Res.
13:2023–2029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Fehm T, Sagalowsky A, Clifford E, et al:
Cytogenetic evidence that circulating epithelial cells in patients
with carcinoma are malignant. Clin Cancer Res. 8:2073–2084.
2002.
|
|
30.
|
Husemann Y, Geigl JB, Schubert F, et al:
Systemic spread is an early step in breast cancer. Cancer Cell.
13:58–68. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Meng S, Tripathy D, Frenkel EP, et al:
Circulating tumor cells in patients with breast cancer dormancy.
Clin Cancer Res. 10:8152–8162. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Kallergi G, Mavroudis D, Georgoulias V and
Stournaras C: Phosphorylation of FAK, PI-3K, and impaired actin
organization in CK-positive micrometastatic breast cancer cells.
Mol Med. 13:79–88. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Kallergi X, Kallergi G, Agelaki S, et al:
Phosphorylated EGFR and PI-3K/Akt signaling kinases are expressed
in circulating tumor cells of breast cancer patients. Breast Cancer
Res. 10:R802008. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Lurje G and Lenz HJ: EGFR signaling and
drug discovery. Oncology. 77:400–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Lurje G, Schiesser M, Claudius A and
Schneider PM: Circulating tumor cells in gastrointestinal
malignancies: current techniques and clinical implications. J
Oncol. 2010:3926522010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Taubert H, Blumke K, Bilkenroth U, et al:
Detection of disseminated tumor cells in peripheral blood of
patients with breast cancer: correlation to nodal status and
occurrence of metastases. Gynecol Oncol. 92:256–261. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Vona G, Sabile A, Louha M, et al:
Isolation by size of epithelial tumor cells: a new method for the
immunomorphological and molecular characterization of circulating
tumor cells. Am J Pathol. 156:57–63. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Pinzani P, Salvadori B, Simi L, et al:
Isolation by size of epithelial tumor cells in peripheral blood of
patients with breast cancer: correlation with real-time reverse
transcriptase-polymerase chain reaction results and feasibility of
molecular analysis by laser microdissection. Hum Pathol.
37:711–718. 2006. View Article : Google Scholar
|
|
39.
|
Muller V, Alix-Panabieres C and Pantel K:
Insights into minimal residual disease in cancer patients:
implications for anti-cancer therapies. Eur J Cancer. 46:1189–1197.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Deng G, Herrler M, Burgess D, Manna E,
Krag D and Burke JF: Enrichment with anti-cytokeratin alone or
combined with anti-EpCAM antibodies significantly increases the
sensitivity for circulating tumor cell detection in metastatic
breast cancer patients. Breast Cancer Res. 10:R692008. View Article : Google Scholar
|
|
41.
|
Balic M, Dandachi N, Hofmann G, et al:
Comparison of two methods for enumerating circulating tumor cells
in carcinoma patients. Cytometry B Clin Cytom. 68:25–30. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Gertler R, Rosenberg R, Fuehrer K, Dahm M,
Nekarda H and Siewert JR: Detection of circulating tumor cells in
blood using an optimized density gradient centrifugation. Recent
Results Cancer Res. 162:149–155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Stott SL, Lee RJ, Nagrath S, et al:
Isolation and characterization of circulating tumor cells from
patients with localized and metastatic prostate cancer. Sci Transl
Med. 2:25ra232010. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Flores LM, Kindelberger DW, Ligon AH, et
al: Improving the yield of circulating tumour cells facilitates
molecular characterisation and recognition of discordant HER2
amplification in breast cancer. Br J Cancer. 102:1495–1502. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Allard WJ, Matera J, Miller MC, et al:
Tumor cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients with
nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Mostert B, Kraan J, Bolt-de Vries J, et
al: Detection of circulating tumor cells in breast cancer may
improve through enrichment with anti-CD146. Breast Cancer Res
Treat. April 9–2010.(Epub ahead of print).
|
|
47.
|
Fehm T, Solomayer EF, Meng S, et al:
Methods for isolating circulating epithelial cells and criteria for
their classification as carcinoma cells. Cytotherapy. 7:171–185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Ring AE, Zabaglo L, Ormerod MG, Smith IE
and Dowsett M: Detection of circulating epithelial cells in the
blood of patients with breast cancer: comparison of three
techniques. Br J Cancer. 92:906–912. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Katz RL, He W, Khanna A, et al:
Genetically abnormal circulating cells in lung cancer patients: an
antigen-independent fluorescence in situ hybridization-based
case-control study. Clin Cancer Res. 16:3976–3987. 2010. View Article : Google Scholar
|
|
50.
|
Maheswaran S, Sequist LV, Nagrath S, et
al: Detection of mutations in EGFR in circulating lung-cancer
cells. N Engl J Med. 359:366–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Cohen SJ, Punt CJ, Iannotti N, et al:
Relationship of circulating tumor cells to tumor response,
progression-free survival, and overall survival in patients with
metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Ntouroupi TG, Ashraf SQ, McGregor SB, et
al: Detection of circulating tumour cells in peripheral blood with
an automated scanning fluorescence microscope. Br J Cancer.
99:789–795. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Leversha MA, Han J, Asgari Z, et al:
Fluorescence in situ hybridization analysis of circulating tumor
cells in metastatic prostate cancer. Clin Cancer Res. 15:2091–2097.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Wu CH, Lin SR, Yu FJ, et al: Development
of a high-throughput membrane-array method for molecular diagnosis
of circulating tumor cells in patients with gastric cancers. Int J
Cancer. 19:373–379. 2006.PubMed/NCBI
|
|
55.
|
Galanzha EI, Shashkov EV, Spring PM, Suen
JY and Zharov VP: In vivo, noninvasive, label-free detection and
eradication of circulating metastatic melanoma cells using
two-color photoacoustic flow cytometry with a diode laser. Cancer
Res. 69:7926–7934. 2009. View Article : Google Scholar
|
|
56.
|
Kojima T, Hashimoto Y, Watanabe Y, et al:
A simple biological imaging system for detecting viable human
circulating tumor cells. J Clin Invest. 119:3172–3181. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Krivacic RT, Ladanyi A, Curry DN, et al: A
rare-cell detector for cancer. Proc Natl Acad Sci USA.
101:10501–10504. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Marrinucci D, Bethel K, Lazar D, et al:
Cytomorphology of circulating colorectal tumor cells: a small case
series. J Oncol. 2010:8613412010. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Vermeulen L, Sprick MR, Kemper K, Stassi G
and Medema JP: Cancer stem cells – old concepts, new insights. Cell
Death Differ. 15:947–958. 2008.
|
|
61.
|
Lin EH, Hassan M, Li Y, et al: Elevated
circulating endothelial progenitor marker CD133 messenger RNA
levels predict colon cancer recurrence. Cancer. 110:534–542. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Theodoropoulos PA, Polioudaki H, Agelaki
S, et al: Circulating tumor cells with a putative stem cell
phenotype in peripheral blood of patients with breast cancer.
Cancer Lett. 288:99–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Tanaka F, Yoneda K, Kondo N, et al:
Circulating tumor cells as a diagnostic marker in primary lung
cancer. Clin Cancer Res. 15:6980–6986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Budd GT, Cristofanilli M, Ellis MJ, et al:
Circulating tumor cells versus imaging – predicting overall
survival in metastatic breast cancer. Clin Cancer Res.
12:6403–6409. 2006.
|
|
65.
|
Moreno JG, Miller MC, Gross S, Allard WJ,
Gomella LG and Terstappen LW: Circulating tumor cells predict
survival in patients with metastatic prostate cancer. Urology.
65:713–718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Stathopoulou A, Vlachonikolis I, Mavroudis
D, et al: Molecular detection of cytokeratin-19-positive cells in
the peripheral blood of patients with operable breast cancer:
evaluation of their prognostic significance. J Clin Oncol.
20:3404–3412. 2002. View Article : Google Scholar
|
|
67.
|
Ignatiadis M, Xenidis N, Perraki M, et al:
Different prognostic value of cytokeratin-19 mRNA positive
circulating tumor cells according to estrogen receptor and HER2
status in early-stage breast cancer. J Clin Oncol. 25:5194–5202.
2007. View Article : Google Scholar
|
|
68.
|
Allen-Mersh TG, McCullough TK, Patel H,
Wharton RQ, Glover C and Jonas SK: Role of circulating tumour cells
in predicting recurrence after excision of primary colorectal
carcinoma. Br J Surg. 94:96–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Cohen SJ, Punt CJ, Iannotti N, et al:
Prognostic significance of circulating tumor cells in patients with
metastatic colorectal cancer. Ann Oncol. 20:1223–1229. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Halabi S, Small EJ, Hayes DF, Vogelzang NJ
and Kantoff PW: Prognostic significance of reverse transcriptase
polymerase chain reaction for prostate-specific antigen in
metastatic prostate cancer: a nested study within CALGB 9583. J
Clin Oncol. 21:490–495. 2003. View Article : Google Scholar
|
|
71.
|
Payne RE, Yague E, Slade MJ, et al:
Measurements of EGFR expression on circulating tumor cells are
reproducible over time in metastatic breast cancer patients.
Pharmacogenomics. 10:51–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Liu Z, Jiang M, Zhao J and Ju H:
Circulating tumor cells in perioperative esophageal cancer
patients: quantitative assay system and potential clinical utility.
Clin Cancer Res. 13:2992–2997. 2007. View Article : Google Scholar
|
|
73.
|
Yen LC, Yeh YS, Chen CW, et al: Detection
of KRAS oncogene in peripheral blood as a predictor of the response
to cetuximab plus chemotherapy in patients with metastatic
colorectal cancer. Clin Cancer Res. 15:4508–4513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Yang MJ, Chiu HH, Wang HM, et al:
Enhancing detection of circulating tumor cells with activating KRAS
oncogene in patients with colorectal cancer by weighted
chemiluminescent membrane array method. Ann Surg Oncol. 17:624–633.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Larson CJ, Moreno JG, Pienta KJ, et al:
Apoptosis of circulating tumor cells in prostate cancer patients.
Cytometry A. 62:46–53. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Gradilone A, Petracca A, Nicolazzo C, et
al: Prognostic significance of survivin-expressing circulating
tumour cells in T1G3 bladder cancer. BJU Int. 106:710–715. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH
and Kim CW: TTF-1 mRNA-positive circulating tumor cells in the
peripheral blood predict poor prognosis in surgically resected
non-small cell lung cancer patients. Lung Cancer. May 13–2010.(Epub
ahead of print).
|
|
78.
|
Barbu V, Bonnand AM, Hillaire S, et al:
Circulating albumin messenger RNA in hepatocellular carcinoma:
results of a multicenter prospective study. Hepatology.
26:1171–1175. 1997.PubMed/NCBI
|
|
79.
|
Bessa X, Pinol V, Castellvi-Bel S, et al:
Prognostic value of postoperative detection of blood circulating
tumor cells in patients with colorectal cancer operated on for
cure. Ann Surg. 237:368–375. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
80.
|
Meng S, Tripathy D, Shete S, et al: HER-2
gene amplification can be acquired as breast cancer progresses.
Proc Natl Acad Sci USA. 101:9393–9398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
81.
|
Meng S, Tripathy D, Shete S, et al: uPAR
and HER-2 gene status in individual breast cancer cells from blood
and tissues. Proc Natl Acad Sci USA. 103:17361–17365. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
82.
|
Wulfing P, Borchard J, Buerger H, et al:
HER2-positive circulating tumor cells indicate poor clinical
outcome in stage I to III breast cancer patients. Clin Cancer Res.
12:1715–1720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
83.
|
Pestrin M, Bessi S, Galardi F, et al:
Correlation of HER2 status between primary tumors and corresponding
circulating tumor cells in advanced breast cancer patients. Breast
Cancer Res Treat. 118:523–530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
84.
|
Slade MJ, Payne R, Riethdorf S, et al:
Comparison of bone marrow, disseminated tumour cells and
blood-circulating tumour cells in breast cancer patients after
primary treatment. Br J Cancer. 100:160–166. 2009. View Article : Google Scholar
|
|
85.
|
Smith SL and Rajan PS: Imaging of
pancreatic adenocarcinoma with emphasis on multidetector CT. Clin
Radiol. 59:26–38. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
86.
|
De Giorgi U, Valero V, Rohren E, et al:
Circulating tumor cells and [18F]flurodeoxyglucose positron
emission tomography/computed tomography for outcome prediction in
metastatic breast cancer. J Clin Oncol. 27:3303–3311. 2009.
|
